DOCSLIB.ORG

Emergency Use Authorization (EUA)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Emergency Use Authorization (EUA) May 26, 2021 GlaxoSmithKline LLC Attention: Debra H. Lake, M.S. Senior Director, Global Regulatory Affairs Five Moore Drive PO Box 13398 Durham, North Carolina 27709 RE: Emergency Use Authorization 100 Dear Ms. Lake: This letter is in response to GlaxoSmithKline LLC’s (GSK) request that the Food and Drug Administration (FDA) issue an Emergency Use Authorization (EUA) for the emergency use of sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19), as described in the Scope of Authorization (Section II) of this letter, pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. §360bbb-3). On February 4, 2020, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes coronavirus disease 2019 (COVID-19).1 On the basis of such determination, the Secretary of HHS on March 27, 2020, declared that circumstances exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic, pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360bbb-3), subject to terms of any authorization issued under that section.2 Sotrovimab is a recombinant human IgG1κ monoclonal antibody that binds to a conserved epitope on the spike protein receptor binding domain of SARS-CoV-2. Sotrovimab does not compete with human ACE2 receptor binding. Sotrovimab is an investigational drug and is not currently approved for any indication. Based on review of the interim analysis of phase 1/2/3 data from the COMET-ICE clinical trial (NCT #04545060), a randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of sotrovimab 500 mg IV in outpatient (non-hospitalized) adults with SARS- CoV-2 infection, it is reasonable to believe that sotrovimab may be effective for the treatment of 1 U.S. Department of Health and Human Services, Determination of a Public Health Emergency and Declaration that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3. February 4, 2020. 2 U.S. Department of Health and Human Services, Declaration that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3, 85 FR 18250 (April 1, 2020). Page 2 – GlaxoSmithKline mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and when used under the conditions described in this authorization, the known and potential benefits of sotrovimab outweigh the known and potential risks of such product. Having concluded that the criteria for issuance of this authorization under Section 564(c) of the Act are met, I am authorizing the emergency use of sotrovimab for treatment of COVID-19, as described in the Scope of Authorization section of this letter (Section II) and subject to the terms of this authorization. I. Criteria for Issuance of Authorization I have concluded that the emergency use of sotrovimab for the treatment of COVID-19 when administered as described in the Scope of Authorization (Section II) meets the criteria for issuance of an authorization under Section 564(c) of the Act, because: 1. SARS-CoV-2 can cause a serious or life-threatening disease or condition, including severe respiratory illness, to humans infected by this virus; 2. Based on the totality of scientific evidence available to FDA, it is reasonable to believe that sotrovimab may be effective in treating mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and that, when used under the conditions described in this authorization, the known and potential benefits of sotrovimab outweigh the known and potential risks of such products; and 3. There is no adequate, approved, and available alternative to the emergency use of sotrovimab for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.3 II. Scope of Authorization I have concluded, pursuant to Section 564(d)(1) of the Act, that the scope of this authorization is limited as follows: • Sotrovimab will be used only by healthcare providers to treat mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death; 3 No other criteria of issuance have been prescribed by regulation under Section 564(c)(4) of the Act. Page 3 – GlaxoSmithKline • Sotrovimab is not authorized for use in the following patient populations4: • Adults or pediatric patients who are hospitalized due to COVID-19, or • Adults or pediatric patients who require oxygen therapy due to COVID- 19, or • Adults or pediatric patients who require an increase in baseline oxygen flow rate due to COVID-19 in those patients on chronic oxygen therapy due to underlying non-COVID-19-related comorbidity. • Sotrovimab may only be administered in settings in which health care providers have immediate access to medications to treat a severe infusion reaction, such as anaphylaxis, and the ability to activate the emergency medical system (EMS), as necessary. • The use of sotrovimab covered by this authorization must be in accordance with the authorized Fact Sheets. Product Description Sotrovimab is supplied in individual single dose vials. Individual vials and carton container labeling for sotrovimab are clearly marked “For use under Emergency Use Authorization.” Sotrovimab is a recombinant human IgG1κ monoclonal antibody that binds to a conserved epitope on the spike protein receptor binding domain of SARS-CoV-2. Sotrovimab does not compete with human ACE2 receptor binding. Sotrovimab is available as a 500 mg/8 mL (62.5 mg/mL) sterile, preservative-free, clear, colorless or yellow to brown solution to be diluted prior to infusion. Unopened vials of sotrovimab should be stored under refrigerated temperature at 2°C to 8°C (36°F to 46°F). The vials should be kept in the individual original cartons to protect from light. The diluted infusion solution of sotrovimab should be administered immediately. If immediate administration is not possible, store the diluted infusion solution for up to 24 hours at refrigerated temperature (2°C to 8°C [36°F to 46°F]) or up to 4 hours at room temperature (20°C to 25°C [68°F to 77°F]) including transportation and infusion time. Each carton containing a single treatment course of the authorized sotrovimab will include a single copy each of the following product-specific documents detailing information pertaining to its emergency use (referred to as “authorized labeling”)5: • Fact Sheet for Healthcare Providers: Emergency Use Authorization (EUA) of sotrovimab • Fact Sheet for Patients, Parents and Caregivers: Emergency Use Authorization (EUA) of sotrovimab for the treatment Coronavirus Disease 2019 (COVID-19) 4 Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID-19. SARS- CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID 19 requiring high flow oxygen or mechanical ventilation. 5 The authorized labeling for EUA 100 will also be available on GSK’s website at www.sotrovimab.com Page 4 – GlaxoSmithKline I have concluded, pursuant to Section 564(d)(2) of the Act, that it is reasonable to believe that the known and potential benefits of sotrovimab, when used for the treatment of COVID-19 and used in accordance with this Scope of Authorization (Section II), outweigh the known and potential risks. I have concluded, pursuant to Section 564(d)(3) of the Act, based on the totality of scientific evidence available to FDA, that it is reasonable to believe that sotrovimab may be effective for the treatment of COVID-19 when used in accordance with this Scope of Authorization (Section II), pursuant to Section 564(c)(2)(A) of the Act. Having reviewed the scientific information available to FDA, including the information supporting the conclusions described in Section I above, I have concluded that sotrovimab (as described in this Scope of Authorization (Section II)) meets the criteria set forth in Section 564(c) of the Act concerning safety and potential effectiveness. The emergency use of your product under an EUA must be consistent with, and may not exceed, the terms of the Authorization, including the Scope of Authorization (Section II) and the Conditions of Authorization (Section III). Subject to the terms of this EUA and under the circumstances set forth in the Secretary of HHS's determination under Section 564(b)(1)(C) described above and the Secretary of HHS’s corresponding declaration under Section 564(b)(1), sotrovimab is authorized to treat mild- to-moderate COVID-19 illness in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, who are at high risk for progression to severe COVID-19, including hospitalization or death, as described in the Scope of Authorization (Section II) under this EUA, despite the fact that it does not meet certain requirements otherwise required by applicable federal law.
Load more

Recommended publications
  • Emergency Use Authorization (EUA) for Sotrovimab 500 Mg Center for Drug Evaluation and Research (CDER) Review
    Emergency Use Authorization (EUA) for Sotrovimab 500 mg Center for Drug Evaluation and Research (CDER) Review Identifying Information Application Type EUA (EUA or Pre-EUA) If EUA, designate whether pre-event or intra-event EUA request. EUA Application EUA 000100 Number(s) Sponsor (entity EUA Sponsor requesting EUA or GlaxoSmithKline Research & Development Limited pre-EUA 980 Great West Road consideration), point Brentford Middlesex, TW8 9GS of contact, address, UK phone number, fax number, email GSK US Point of Contact address Debra H. Lake, M.S. Sr. Director Global Regulatory Affairs GlaxoSmithKline 5 Moore Drive PO Box 13398 Research Triangle Park, NC 27709-3398 (b) (6) Email: Phone Manufacturer, if GlaxoSmithKline, Parma. different from Sponsor Submission Date(s) Part 1: March 24, 2021 Part 2: March 29, 2021 Receipt Date(s) Part 1: March 24, 2021 Part 2: March 29, 2021 OND Division / Office Division of Antivirals /Office of Infectious Disease 1 Reference ID: 4802027 Product in the No Strategic National Stockpile (SNS) Distributor, if other (b) (4) than Sponsor I. EUA Determination/Declaration On February 4, 2020, the Secretary of Health and Human Services determined pursuant to section 564 of the Federal Food, Drug and Cosmetic (FD&C) Act that there is a public health emergency that has a significant potential to affect national security or the health and security of United States (US) citizens living abroad and that involves a novel (new) coronavirus (nCoV) first detected in Wuhan City, Hubei Province, China in 2019 (2019-nCoV). The virus is now named SARS-CoV-2, which causes the illness COVID-19.
    [Show full text]
  • Updates on COVID-19 Monoclonal Antibody Treatment In
    Updates on COVID-19 Monoclonal Antibody (mAb) Treatment in the Outpatient Setting Overview • All providers should know how and when to refer patients for monoclonal antibody (mAB) treatment. • mAb treatment, when given early after symptom onset, can decrease the risk of hospitalization and death due to COVID-19 by as much as 70% to 85%. • Eligibility criteria for mAb treatment have been expanded to include additional medical conditions and factors that may place patients at high risk for progression to severe COVID-19. • Continue to refer eligible symptomatic patients for mAb treatment, regardless of vaccination status. • Sotrovimab is a new mAb product that has been granted emergency use authorization (EUA) by the Food and Drug Administration (FDA). • The EUA for REGEN-COV (casirivimab + imdevimab) has been updated to reduce the dose and allow for subcutaneous administration. • The EUA for REGEN-COV has also been expanded to include use as post-exposure prophylaxis for people exposed to someone with COVID-19 and at high risk for severe illness. • Health care providers should use only REGEN-COV or sotrovimab for the treatment of COVID-19 until further notice due to increasing prevalence of SARS-CoV-2 variants resistant to bamlanivimab and etesevimab. August 20, 2021 Dear Colleague, This letter summarizes important updates on monoclonal antibody (mAb) emergency use authorizations (EUAs) and treatment guidance. mAbs are the only authorized treatment option for patients with mild to moderate COVID-19 who are at high risk of developing severe illness. It is also the only option for post-exposure prophylaxis (PEP). As cases of COVID-19 continue to rise in New York City (NYC) due to more contagious and dangerous variants, it is critical that providers assist eligible patients to access this life-saving treatment by increasing patient awareness, encouraging prompt diagnostic testing following a COVID-19 exposure or symptom onset, and offering or referring patients for treatment.
    [Show full text]
  • Policy Brief 002 Update 07.2021
    Content ................................................................................................................................................................ 3 1 Background: policy question and methods ................................................................................................. 7 1.1 Policy Question ............................................................................................................................................. 7 1.2 Methodology ................................................................................................................................................. 7 1.3 Selection of Products for “Vignettes” ........................................................................................................ 10 2 Results: Vaccines ......................................................................................................................................... 13 2.1 Moderna Therapeutics—US National Institute of Allergy ..................................................................... 25 2.2 University of Oxford/ Astra Zeneca .......................................................................................................... 26 2.3 BioNTech/Fosun Pharma/Pfizer .............................................................................................................. 27 2.4 Janssen Pharmaceutical/ Johnson & Johnson .......................................................................................... 29 2.5 Novavax ......................................................................................................................................................
    [Show full text]
  • FCDPH- Health Update- Monoclonal Antibody Treatments for COVID-19
    County of Fresno DEPARTMENT OF PUBLIC HEALTH Health Update August 16, 2021 Monoclonal Antibody Treatments for COVID-19 On January 4, 2021, The Fresno County Department of Public Health (FCDPH) recommended monoclonal antibodies as COVID-19 treatment options available to healthcare providers. The U.S. Food and Drug Administration (FDA) has updated the Fact Sheet on the availability of REGEN-COV (casirivimab and imdevimab, administered together) monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19. Currently, casirivimab/imdevimab (REGEN-COV or Regeneron) and Sotrovimab have FDA EUA authorization for use in mild to moderate COVID-19. Sites offering MAB treatments are listed on page 5 of this Health Update. Monoclonal antibodies are an important tool in keeping patients from deteriorating and to assist the health care system from becoming overwhelmed. Preliminary data suggests a 2/3 to 3/4 reduction in emergency room visits and hospitalizations among high-risk COVID-19 positive patients who received monoclonal antibodies. Currently approved MABs have been shown to be effective against current variants including Delta. https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/summary- recommendations/ https://science.sciencemag.org/content/371/6531/850 Who is Eligible to Receive Monoclonal Antibodies? Monoclonal antibodies have Federal Drug Administration (FDA) emergency use approval for the treatment of mild to moderate COVID-19 positive patients within the first 10 days of diagnosis
    [Show full text]
  • COVID-19 (Updated 06/29/2021)
    COVID-19 (Updated 06/29/2021) TABLE OF CONTENTS What’s New: ............................................................................................................................................ 2 Coding for COVID-19 ............................................................................................................................... 3 Coding for Confirmed COVID-19 .............................................................................................................. 4 Coding for Exposure to COVID-19 ............................................................................................................ 5 Coding for Screening of COVID-19 ........................................................................................................... 5 Coding for Preprocedural or Admission Protocol COVID-19 ..................................................................... 6 Coding for Signs and Symptoms without a Definitive Diagnosis of COVID-19............................................ 7 COVID-19 Specimen Collection ................................................................................................................ 7 Inpatient Treatment for COVID-19 ........................................................................................................... 8 No Positive COVID-19 test result available ............................................................................................... 8 PHE Status Renewed 4/21/2021 -- Another 90 Days (July 20, 2021) ........................................................
    [Show full text]
  • Emerging Treatment Update: Suspected COVID-19 P.1
    Indian Health Service National Pharmacy and Therapeutics Committee COVID-19 Emerging Treatments Update June 29, 2021 Pause in Distribution and Utilization of Bamlanivimab/Etesevimab On June 25, 2021, the HHS Assistant Secretary for Preparedness and Response (ASPR) announced an immediate pause involving distribution of bamlanivimab and etesevimab together and etesevimab alone (to pair with an existing supply of bamlanivimab) on a national basis until further notice. In addition, the FDA recommends that health care providers nationwide use alternative authorized monoclonal antibody therapies (REGEN-COV and Sotrovimab), as described below, and to avoid use of bamlanivimab and etesevimab administered together for the management of COVID-19 at this time.1 The Centers for Disease Control and Prevention has identified that the combined frequencies of the SARS-CoV-2 P.1/Gamma variant (first identified in Brazil) and the B.1.351/Beta variant (first identified in South Africa) throughout the United States now exceed 11% and are trending upward (https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-proportions.html).2 Results from in-vitro assays used to assess the susceptibility of viral variants to particular monoclonal antibodies suggest that bamlanivimab and etesevimab administered together are not active against either the P.1 or B.1.351 variants. Lack of bamlanivimab/etesevimab activity against the COVID-19 P.1 variant has been suspected and reported earlier.3 REGEN-COV and sotrovimab are alternative monoclonal antibody therapies that are currently authorized for the same use as bamlanivimab and etesevimab administered together. Based on similar in-vitro assay data currently available, REGEN-COV and sotrovimab are likely to retain activity against the P.1 or B.1.351 variants.
    [Show full text]
  • Assessment Report
    20 May 2021 EMA/304600/2021 Committee for Medicinal Products for Human Use (CHMP) Assessment report Procedure under Article 5(3) of Regulation (EC) No 726/2004 GlaxoSmithKline use of sotrovimab (VIR-7831/GSK4182136) for the treatment of COVID-19 INN/active substance: sotrovimab Procedure number: EMEA/H/A-5(3)/1508 Note: Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ......................................................................................... 2 1. Information on the procedure ................................................................. 3 2. Scientific discussion ................................................................................ 3 2.1. Introduction ...................................................................................................... 3 2.2. Clinical aspects .................................................................................................. 4 2.2.1. Clinical pharmacology ...................................................................................... 6 2.2.2. Data on efficacy ...........................................................................................
    [Show full text]
  • EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology's
    CORRECTION -- EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19 May 21, 2021 – Opinion based on the EMA’s Committee for Human Medicinal Products (CHMP) review of available data on sotrovimab (previously VIR-7831) for the early treatment of COVID-19 – – EU member states can use the CHMP positive scientific opinion when making national decisions about the early use of sotrovimab prior to EMA marketing authorization – – Discussions with global regulators regarding authorizations in additional countries continue to advance – LONDON and SAN FRANCISCO, May 21, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Vir Biotechnology, Inc. please note that the third sub headline of the release has been updated. The corrected release follows: GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced that the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has issued a positive scientific opinion following the referral of sotrovimab to the CHMP under Article 5(3) of Regulation 726/2004. The opinion relates to the use of sotrovimab for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19. The CHMP opinion under Article 5(3) can now be considered by the national authorities in EU member states when taking evidence-based decisions on the early use of the medicine prior to marketing authorization. Christopher Corsico, senior vice president, development, GSK, said: “As the COVID-19 pandemic continues and the virus generates new variants of concern, including those that recently emerged in India, the need for therapies that can slow the progression of disease in patients who are at high risk for developing severe complications remains a top priority.
    [Show full text]
  • Monoclonal Antibody (MAB) Therapy Infusion Resources in Alameda
    Alameda County Health Care Services Agency Colleen Chawla, Director Public Health Department Kimi Watkins-Tartt, Director www.acphd.org Nicholas Moss, MD, Health Officer Public Health Department: Main Line (510) 267-8000 COVID-19 Information: (510) 268-2101 COVID-19 Vaccine Appointments: (510) 268-4829 Alameda County Health Advisory Monoclonal Antibody (MAB) Therapy Outpatient Infusion Resources in Alameda County March 8, 2021 (Revised September 20, 2021) Revisions in Red The purpose of this Health Advisory is to inform clinicians in Alameda County about the availability of outpatient monoclonal antibody (MAB) therapy for high-risk patients with mild to moderate SARS-CoV-2 infections who are not yet hospitalized due to COVID. In addition, REGEN-COV and bamlanivimab + etesevimab are now authorized for use as post-exposure prophylaxis (PEP) for patients who are at high risk for progression to severe COVID-19. MAB therapy is recommended in the NIH COVID-19 Treatment Guidelines. Casirivimab + imdevimab (i.e. REGEN-COV), bamlanivimab + etesevimab and sotrovimab are investigational MAB products available under Emergency Use Authorization (EUA) from the FDA. Because the combination of bamlanivimab + etesevimab retains activity against the Delta variant, their use and distribution have been resumed. All of these MAB products have been engineered to bind to and neutralize SARS-CoV-2 and prevent progression to severe illness. There are data suggesting that early outpatient treatment with MAB therapy may shorten the duration of symptoms; decrease the viral load; and prevent some ED visits, hospitalizations, and deaths in high-risk individuals. REGEN-COV is approved for subcutaneous injection as an alternative when intravenous (IV) infusion is not feasible and would lead to delay in treatment.
    [Show full text]
  • Administering Monoclonal Antibody Treatments for COVID-19 in Your Facility
    Administering Monoclonal Antibody Treatments for COVID-19 in Your Facility The following summary can help you prepare your site to administer monoclonal antibody treatment. Plan* ☐ Prepare your facility to participate in monoclonal ☐ Develop a process to gain patient consent antibody administration for COVID-19. for treatment as indicated by local and state • Healthcare providers can only administer monoclonal requirements. antibodies for COVID-19 in settings where providers have ☐ Develop appropriate isolation and infection immediate access to medications to treat a potential severe control procedures. infusion reaction (such as anaphylaxis) and the ability to activate the emergency medical system (EMS), as necessary. ☐ Ensure a dedicated source of supplies, ☐ Determine how to allocate dedicated clinical space. including product. • The U.S. Government developed a process for sites to ☐ Plan to effectively manage patient flow. directly order monoclonal antibodies from the distributor, ☐ Develop your process for patient screening. AmerisourceBergen (ABC). An Overview of Direct Order Process for COVID-19 Therapeutics is available at: • Under the EUA, healthcare providers are authorized to https://www.phe.gov/emergency/events/COVID19/ administer monoclonal antibodies to patients if they investigation-MCM/Documents/Overview%20of%20direct%20 have experienced the onset of mild to moderate symptoms of order%20process%20Fact%20Sheet-508.pdf COVID-19 in the last 10 days, have tested positive for COVID-19, and have one or more of the following ☐ Establish a process for reimbursement for high-risk factors.1 administrative costs. *Infusion locations should consider all local and state requirements. ☐ Develop a referral pathway for providers. Implement ☐ Assign sufficient personnel and resources to manage expected patient demand.
    [Show full text]
  • TAG Mail – 26 August 2021 COVID-19 RESOURCES & ARTICLES of INTEREST Please Click This Link for the Cumulative Listing of COVID-19 Resources in Past TAG Mails
    TAG Mail: July to December 2021 Cumulative Listing of Reports, Publications, Medication Safety TAG Mail – 26 August 2021 COVID-19 RESOURCES & ARTICLES OF INTEREST Please click this link for the cumulative listing of COVID-19 resources in past TAG Mails. AUSTRALIAN Agency for Clinical Innovation, NSW (ACI) - Caring for adults with COVID-10 in the community. Updated guide to care for adults with Delta variant - link Australian Government Department of Health - ATAGI update following weekly COVID-19 meeting 18 August 2021 - link - PHLN and CDNA joint statement on SARS-CoV-2 rapid antigen tests (updated 23/8/21) - link - Shared decision making guide to COVID-19 vaccination for women who are pregnant, breastfeeding or planning pregnancy - link, factsheets in English and other languages - COVID-19 National Health Plan: Prescriptions via telehealth. Guides for prescribers & pharmacists - ATAGI clinical guidance on COVID-19 vaccine in Australia in 2021 (updated 20/8/21) - link MJA Podcasts - Episode 33: COVID-19 in children National COVID-19 Clinical Evidence Taskforce - Taskforce makes new conditional recommendation for sotrovimab - link - New immunodulatory treatments comparison table - link - Tocilizumab and baricitinib FAQs - Ivermectin FAQs NSW Health - COVID-19 vaccination for workers - link - COVID-19 Weekly Surveillance in NSW - Epidemiological week 31, ending 7 August 2021 - link - Safety Notice 018/21: Myocarditis and pericarditis after mRNA COVID-19 vaccines - Statewide Protocol for the Supply or Administration of COVID-19 Vaccine. PD2021_032 (13/08/21) - New ‘find the facts’ webpage which provides data on COVID-19 cases, testing and vaccination and maps showing case numbers and vaccination rates based on location.
    [Show full text]
  • Health Update August 24, 2021
    County of Fresno DEPARTMENT OF PUBLIC HEALTH Health Update August 24, 2021 Monoclonal Antibody Treatments for COVID-19 On January 4, 2021, The Fresno County Department of Public Health (FCDPH) recommended monoclonal antibodies as COVID-19 treatment options available to healthcare providers. This health update includes one (1) NEW Monoclonal Antibody provider site for Fresno County: Fresno Nephrology Group. Sites offering MAB treatments are updated on page 5 of this Health Update. Monoclonal antibodies are an important tool in keeping patients from deteriorating and to assist the health care system from becoming overwhelmed. Preliminary data suggests a 2/3 to 3/4 reduction in emergency room visits and hospitalizations among high-risk COVID-19 positive patients who received monoclonal antibodies. Currently approved MABs have been shown to be effective against current variants including Delta. https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/summary- recommendations/ https://science.sciencemag.org/content/371/6531/850 Who is Eligible to Receive Monoclonal Antibodies? Monoclonal antibodies have Federal Drug Administration (FDA) emergency use approval for the treatment of mild to moderate COVID-19 positive patients within the first 10 days of diagnosis who are at high risk for progressing to severe COVID-19 and/or hospitalization. High risk is defined as patients who meet at least one of the following criteria: • Have a body mass index (BMI) ≥35 • Have chronic kidney disease • Have diabetes • Have
    [Show full text]